IL6 and Insulin resistance: Considering that CTRP3 is an anti-inflammatory mediator, being also negatively associated with the proinflammatory cytokines TNF, IL-6, and C-reactive protein [13,14,44] as well as enhancing glucose tolerance [8,15], we can conclude from the obtained results that the decrease of cartonectin concentration in blood plasma of patients subjected to a 6-month therapy with an insulin mix was associated with reducing inflammation and insulin resistance in these patients.